Liver Cancer
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 15, 2003; 9(9): 1950-1953
Published online Sep 15, 2003. doi: 10.3748/wjg.v9.i9.1950
Expression and significance of RhoC gene in hepatocellular carcinoma
Wei Wang, Lian-Yue Yang, Zhi-Li Yang, Gen-Wen Huang, Wei-Qun Lu
Wei Wang, Lian-Yue Yang, Zhi-Li Yang, Gen-Wen Huang, Wei-Qun Lu, Liver Cancer laboratory, Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Author contributions: All authors contributed equally to the work.
Supported by the grant from National Key Technologies R and D Program, No. 2001BA703B05 and the grant from Hunan Province Developing Planning Committee, No. 2001-907
Correspondence to: Lian-Yue Yang, Department of General Surgery, Xiangya Hospital, Changsha, 410008, Hunan Province, China. lianyueyang@hotmail.com
Telephone: +86-731-4327326 Fax: +86-731-4327332
Received: March 4, 2003
Revised: March 23, 2003
Accepted: April 5, 2003
Published online: September 15, 2003

Abstract

AIM: To investigate the expression of RhoC gene in hepatocellular carcinoma (HCC) and to evaluate the relationship between RhoC gene expression and invasion and metastasis of HCC.

METHODS: mRNA expression level of RhoC gene was examined by reverse transcription-polymerase chain reaction (RT-PCR) in 25 cases of HCC and para-cancerous normal liver tissues. In addition, mutation of RhoC gene was examined by polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP).

RESULTS: The mRNA expression levels of RhoC in tumor tissues were significantly higher than those in para-cancerous normal liver tissues (1.8 ± 1.1 vs 1.0 ± 0.7, P < 0.01). The metastatic lesions outside of liver also showed significantly higher RhoC mRNA levels than corresponding tumor tissues in liver (3.3 ± 0.5 vs 2.0 ± 0.7, P < 0.01). There were significant associations between RhoC gene expression and certain clinical and pathological findings, including cell differentiation, vein invasion, number of tumor nodes and metastatic lesions. Mutation of RhoC gene was not found by PCR-SSCP.

CONCLUSION: The RhoC gene may be related to malignant transformation and development of HCC and may play an important role in the invasion and metastasis of HCC by overexpression but not mutation.




INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, and is the second-leading cause of cancer death among males in China[1]. It is generally accepted that the high incidence of recurrence and metastasis is the most crucial prognostic factor for patients with HCC[2]. Transcellular migration of tumor cells through host structures, such as endothelium of blood vessels and methothelium of visceral cavity is crucial in cancer invasion and metastasis[3].

RhoC GTPase is a member of Ras-superfamily of small guanosine triphosphatases (GTPases), which shuttles between an inactive GDP-bound state and an active GTP-bound state and exhibits intrinsic GTPase activities[4]. Activation of Rho protein leads to assembly of the actin-myosin contractile filaments into focal adhesion complexes that lead to cell polarity and facilitate motility[5]. Recently, emerging data have suggested that RhoC gene play important roles in tumorigenesis and metastasis of tumor cell[6]. The expression level of RhoC in metastatic regions of pancreas cancer has been reported to be higher than that in primary lesion[7]. Genome-wide analysis of gene expression has revealed that RhoC gene was involved in vascular invasiveness of hepatocellular carcinoma[8]. We hypothesized that RhoC might play a critical role in tumorigenesis and invasion and metastasis of HCC. In the present study, we investigated the expression of RhoC gene in HCC and evaluated the relationship between RhoC gene expression and clinical and pathological characteristics of HCC.

MATERIALS AND METHODS
Patients and tissue preparation

Twenty-five fresh HCC specimens and corresponding para-cancerous normal liver tissues were obtained by surgical resection in Xiangya Hospital between March 2002 and August 2002. Further more, four cases of corresponding metastatic lesions or hepatic vein tumor thrombosis were obtained as well. The patients with HCC were consisted of 22 men and 3 women and were ranged from 28 to 73 (mean ± SD = 53). We divided the 25 patients from six aspects: tumor < 5 cm in diameter 7 cases and ≥ 5 cm 18 cases, I-II in cell differentiation 9 cases and III-IV 16 cases; the number of tumor nodes ≥ 2 15 cases and < 2 10 cases, with capsule formation 12 cases and without it 13 cases, with microscopy portal vein tumor thrombosis 13 cases and without it 12 cases, with metastatic nodes outside of liver 5 cases and without it 20 cases. All specimens were examined under a microscope after haematoxylin and eosin (H&E) staining.

RNA extraction and RT-PCR

Total RNA was isolated using Trizol reagent (GIBCO BRL, USA) and cDNA was synthesized from the RNA by M-MLV reverse transcriptase (Promega, USA) with oligodT primers (Sangon Technology, CHINA), The primer sequences of RhoC and β2-microglobulin which was used as an internal quantitative control for the amplification were as follows: the upstream primers of RhoC and β2-microglobulin were 5’-TCCTCATCGTCTTCAGCAAG-3’ and 5’-ACCCCCACTGAAAAAG ATGA-3’, the downstream primers of RhoC and β2-microglobulin were 5’-CTGCAATCCGAAAGAAGCTG-3’ and 5’-ATCTTCAAACCTCCATGATG-3’. The condition of PCR was as follows: 32 cycles of denaturing at 94 °C for 40 s, annealing at 56 °C for 30 s and extending at 72 °C for 1 min. The bands representing amplified products were analyzed by Stratagene Eagle-eye scanner. RhoC gene expression was presented by the relative yield of PCR product from target sequence to that from β2-microglobulin gene.

PCR-SSCP-sliver staining analysis

Because RhoC is homologous with ras gene and mutation of ras is frequent in HCC, PCR-SSCP-sliver staining analysis was performed to determine gene mutation of RhoC. We examined exon I of RhoC. The primers were designed as follows: upstream 5’-CTGCAATCCGAAAGAAGCTG-3’ and downstream 5’-CTGCAATCCGAAAGAAGCTG-3’. PCR reaction was performed by denaturing at 94 °C for 40 s, annealing at 55 °C for 30 s and extending at 72 °C for 1 min for 35 cycles. PCR samples were denatured at 99 °C for 10 min and electrophoresed with 8% non-denaturing polyacrylamide gel at 40v for 5 hours. After electrophoresis, the gel was fixed in 10% alcohol for 10 min, washed twice with distilled water for 2 min, silver reaction was performed (silver nitrate 1 g, topped up with distilled water to 500 mL) for 10 min, then washed with distilled water for 30 s, finally the gel was developed (sodium hydroxide 3.75 g, formaldehyde 2.7 mL, topped up with distilled water to 500 mL) for 10 min.

Statistical analysis

The results of RT-PCR were statistically analyzed using the Student’s t test. Fisher’s exact test was used to determine the relationship between RhoC expression and clinical and pathological characteristics of HCC. A value of P < 0.05 was considered statistically significant.

RESULTS

RhoC gene was expressed in HCC tissues and para-cancerous normal liver tissues of all the 25 cases. There were significant differences in the expression level of RhoC gene between carcinoma tissues and para-cancerous normal liver tissues (mean ± SD, 1.8 ± 1.1 vs 1.0 ± 0.7 respectively) (Figure 1). Metastatic lesions or hepatic vein tumor thrombosis showed significantly higher RhoC mRNA levels than primary carcinoma tissues (mean ± SD, 3.3 ± 0.5 vs 1.8 ± 1.1 respectively). Based on the ratio of RhoC expression in tumor to corresponding para-cancerous normal liver tissues (Xt/Xp = 1.8), the 25 patients were divided into two groups: overexpression group (14 cases) and high-expression group (11 cases). Fisher’s exact test analysis demonstrated a significant difference in some aspects between the two groups (P < 0.05) including cell differentiation, vein invasion, number of tumor nodes and metastatic lesions. The difference in vein invasion between the two groups was statistically significant (P < 0.01) (Table 1). Mutation of RhoC was not found in all cases of HCC.

Table 1 The relationship between RhoC mRNA expression and clinical and pathological features of HCC patients.
VariablesOverexpression of RhoC (n)High-expression of RhoC (n)Fisher’s test
Sex
Male1210P > 0.05
Female21
Tumor size (cm)
≥ 5 cm126P > 0.05
< 5 cm25
Histological grade
I-II27P < 0.05
III-IV124
Number of tumor nodes
≥ 2114P < 0.05
< 237
Capsule formation
Positive57P > 0.05
Negative94
Portal vein thrombosis
Positive112P < 0.01
Negative39
Metastatic node out of liver
Present50P < 0.05
Absent911
Figure 1
Figure 1 Expression of RhoC mRNA in hepatocellular carcinoma. M: DNA marker T: tumor P: para-cancerous normal liver tissues. PCR product of RhoC was 183 bp; PCR product of β2-microglobulin was 120 bp. RhoC mRNA levels were signifi-cantly higher in tumor than para-cancerous normal liver tissues.
DISCUSSION

RhoGTPases are members of the ras superfamily of GTP-binding protein, which act as molecular switches, cycling between an active GTP-bound and inactive GDP-bound states. Eighteen members have been identified and the most extensively characterized members are Rho, Rac and cdc42[5]. Early studies showed that Rho protein regulated cell morphology and actin cytoskeleton, however it is now clear that they also affect gene expression, cell proliferation and cell survival[9]. Emerging data have showed that RhoGTPases are more important for the evolution of cancer than initially thought, and several reports indicated that RhoGTPases directly participated in the evolution of cancer. For instance, activated Rho protein mutants were capable of transforming fibroblast and dominant inhibitory mutants of Rho protein blocked transformation by ras[10]. Furthermore, Rho protein could upregulate cyclinD1 and downregulate CDKIS through ETS, AP-1 and NF-KB[11-19]. These indicate that Rho protein is important in tumorigenesis. RhoC is a member of Rho family and it has been shown that overexpression of RhoC induce the malignant transformation of immortalized human mammary epithelial cells. RhoC is overexpressed in pancreatic ductal adenocarcinoma and inflammatory breast cancer[7,20]. Furthermore, there is a causal link between RhoC overexpression and inflammatory breast cancer. Based on these results, we hypothesized that RhoC might be involved in tumorigenesis of HCC. We detected the expression level of RhoC mRNA in 25 patients with HCC by RT-PCR. Our results showed that RhoC gene expression was significantly higher in tumor portion than that in corresponding para-cancerous normal liver tissues. Furthermore, we also found that tumor with RhoC overexpression appeared poorer in cell differentiation than those with high-expression of RhoC gene. These suggest that overexpression of RhoC gene is related to the degree of differentiation of HCC and RhoC expression level could be a useful prognostic indicator.

Metastasis and invasion of HCC were a multistep process, and the molecular and cellular mechanisms of which were not fully understood, although cell motility has been shown to play a pivotal role in metastasis and invasion of HCC[21]. RhoC is involved in cytoskeletal reorganization, specifically in the formation of actin stress fibers and focal adhesion contacts[22]. Numerous in vitro studies have indicated that RhoC protein and its effector ROCK are clearly implicated in vivo models of tumor-cell dissemination[23]. Overexpression of RhoC gene was found in metastatic lesions of inflammatory breast cancer and pancreatic ductal adenocarcinoma. RhoC gene was also found to be correlated with vascular invasion and tumor differentiation in human HCC by using cDNA microarray[8]. In the present study metastatic lesions or hepatic vein tumor thrombosis showed significantly higher RhoC mRNA level than primary carcinoma tissues. Expression level of RhoC gene was correlated with vein invasion, number of tumor nodes and metastatic lesions. Especially, the difference between two groups in microscopy hepatic vein tumor thrombosis indicated greater significance. These results indicate that RhoC has a close relationship with invasion and metastasis of HCC. The possible reasons may be as follows: (1) Disruption of cell polarity, which plays an important role in the epithelial-mesenchymal transformation that is observed in more aggressive tumors[24,25]. (2) Contribution to the loss of adherens junctions[26-28]. (3) Increase of motility and ability to remodel ECM, which requires tumor cells to become locally invasive[29-32]. However, the exact mechanisms need to be explored further.

Given the results that RhoC protein is important in determining the behavior of cancer cells, it is surprising that mutants of RhoC-analogous of oncogenic ras have not been found in our research. Similar results were observed in pancreatic ductal adenocarcinoma[7]. In fact, several lines of evidence indicate that not mutation but the switch of Rho protein between GTP- and GDP-bound states are important in the transformation of malignant tumor[33]. Overexpression level of RhoC may contribute to a faster GTP-GDP cycling station. Taken together, our findings indicate that RhoCGTPase is related to tumorigenesis of HCC. Overexpression but not mutation of RhoC may enhance the invasion and metastasis of HCC. The molecular basis for overexpression of RhoC remains to be elucidated. What are the most important factors regulating the expression level of RhoC and how does RhoC gene regulate effector protein will be the subject of our future studies. When upstream and downstream signaling pathways are explored, these findings will provide new potential targets for the prognostication or prevention of invasion and metastasis of HCC[34].

ACKNOWLEDGEMENTS

We are grateful to Fa-Qing Tang, Jian-Qing Yang, and He-Li Liu for their technical advice and Min-Juan Lin for her statistical support.

Footnotes

Edited by Yuan HT and Wang XL

References
1.  Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.  [PubMed]  [DOI]
2.  Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193-199.  [PubMed]  [DOI]
3.  Korn WM. Moving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol. 2001;7:777-778.  [PubMed]  [DOI]
4.  Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348 Pt 2:241-255.  [PubMed]  [DOI]
5.  Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-2322.  [PubMed]  [DOI]
6.  Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133-142.  [PubMed]  [DOI]
7.  Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer. 1998;77:147-152.  [PubMed]  [DOI]
8.  Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61:2129-2137.  [PubMed]  [DOI]
9.  Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.  [PubMed]  [DOI]
10.  Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci USA. 1995;92:11781-11785.  [PubMed]  [DOI]
11.  Vojtek AB, Cooper JA. Rho family members: activators of MAP kinase cascades. Cell. 1995;82:527-529.  [PubMed]  [DOI]
12.  Marinissen MJ, Chiariello M, Gutkind JS. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway. Genes Dev. 2001;15:535-553.  [PubMed]  [DOI]
13.  Cammarano MS, Minden A. Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem. 2001;276:25876-25882.  [PubMed]  [DOI]
14.  Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 1998;394:295-299.  [PubMed]  [DOI]
15.  Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol. 1998;18:6962-6970.  [PubMed]  [DOI]
16.  Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem. 1997;272:13-16.  [PubMed]  [DOI]
17.  Weber JD, Hu W, Jefcoat SC, Raben DM, Baldassare JJ. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem. 1997;272:32966-32971.  [PubMed]  [DOI]
18.  Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-2400.  [PubMed]  [DOI]
19.  Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-2698.  [PubMed]  [DOI]
20.  van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832-5838.  [PubMed]  [DOI]
21.  Donald CD, Cooper CR, Harris-Hooker S, Emmett N, Scanlon M, Cooke DB. Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell Mol Biol (Noisy-le-grand). 2001;47:1033-1038.  [PubMed]  [DOI]
22.  Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001;114:2713-2722.  [PubMed]  [DOI]
23.  Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406:532-535.  [PubMed]  [DOI]
24.  Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol. 2000;149:775-782.  [PubMed]  [DOI]
25.  Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 2000;269:652-659.  [PubMed]  [DOI]
26.  Braga VM, Betson M, Li X, Lamarche-Vane N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell. 2000;11:3703-3721.  [PubMed]  [DOI]
27.  Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12:27-36.  [PubMed]  [DOI]
28.  Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, Collard JG. Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol. 1998;143:1385-1398.  [PubMed]  [DOI]
29.  Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001;61:3750-3759.  [PubMed]  [DOI]
30.  Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998;140:647-657.  [PubMed]  [DOI]
31.  Engers R, Springer E, Michiels F, Collard JG, Gabbert HE. Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2 expression. J Biol Chem. 2001;276:41889-41897.  [PubMed]  [DOI]
32.  Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res. 2001;92:429-438.  [PubMed]  [DOI]
33.  Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000;19:3013-3020.  [PubMed]  [DOI]
34.  Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002;160:579-584.  [PubMed]  [DOI]